Valuation: Protagonist Therapeutics, Inc.

Market Cap 854.41Cr 766.32Cr 700.35Cr 639.31Cr 1.2TCr 80TCr 1.24TCr 8.44TCr 3.37TCr 43TCr 3.21TCr 3.14TCr 1,35300Cr P/E 2026 *
27.1x
P/E 2027 * -436x
Enterprise Value 801.72Cr 719.06Cr 657.16Cr 599.88Cr 1.13TCr 75TCr 1.17TCr 7.92TCr 3.16TCr 40TCr 3.01TCr 2.94TCr 1,26900Cr EV / Sales 2026 *
14.6x
EV / Sales 2027 * 37.4x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-8.84%
Current month-8.84%
1 month-4.79%
3 months-9.67%
6 months+27.00%
Current year+51.18%
1 week 128
Extreme 128
146
1 month 126.39
Extreme 126.39
152.18
Current year 77
Extreme 77
160.81
1 year 77
Extreme 77
160.81
3 years 14.78
Extreme 14.78
160.81
5 years 6.91
Extreme 6.91
160.81
10 years 4.47
Extreme 4.47
160.81
Manager TitleAgeSince
Chief Executive Officer 69 01/12/2008
Director of Finance/CFO 52 18/04/2022
Chief Tech/Sci/R&D Officer - 01/04/2026
Director TitleAgeSince
Director/Board Member 69 01/12/2008
Chairman 71 19/03/2014
Director/Board Member 69 01/07/2016
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Exercice

Chief Financial Officer

1,75,887 0.2718%
10/09/26 Exercice

Chief Executive Officer

21,834 0.0337%
03/09/26 Don

Chief Executive Officer

-510 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-2.38%-8.84%+65.51%+710.56% 854.41Cr
-4.83%+3.51%+53.62%+61.75% 6.59TCr
-1.34%+2.98%+24.79%+100.18% 5.65TCr
+0.02%+1.07%+10.63%+76.66% 5.69TCr
+5.09%+9.89%+22.45%+107.48% 4.65TCr
+2.62%+1.68%+28.91%+37.01% 4.48TCr
+8.24%+0.51%+213.26%+792.66% 4.16TCr
-1.86%+10.13%+26.82%+53.22% 3.53TCr
-2.97%-9.84%+88.86%+76.17% 3.33TCr
-2.18%+7.06%+36.06%-4.95% 2.49TCr
Average +0.04%+2.04%+57.09%+201.08% 4.14TCr
Weighted average by Cap. +0.16%+3.15%+53.37%+154.66%

Financials

2026 *2027 *
Net sales 55Cr 49Cr 45Cr 41Cr 77Cr 5.16TCr 80Cr 542.45Cr 216.3Cr 2.75TCr 206.08Cr 201.66Cr 8.69TCr 22Cr 19Cr 18Cr 16Cr 30Cr 2.03TCr 31Cr 212.91Cr 85Cr 1.08TCr 81Cr 79Cr 3.41TCr
Net income 33Cr 29Cr 27Cr 24Cr 46Cr 3.07TCr 47Cr 322.29Cr 128.51Cr 1.64TCr 122.44Cr 119.81Cr 5.17TCr -4.77Cr -4.28Cr -3.91Cr -3.57Cr -6.72Cr -448.3Cr -6.94Cr -47Cr -19Cr -239.2Cr -18Cr -18Cr -755.14Cr
Net Debt -53Cr -47Cr -43Cr -39Cr -74Cr -4.95TCr -77Cr -520.59Cr -207.59Cr -2.64TCr -197.78Cr -193.53Cr -8.34TCr -49Cr -44Cr -41Cr -37Cr -70Cr -4.65TCr -72Cr -488.28Cr -194.7Cr -2.48TCr -185.5Cr -181.52Cr -7.83TCr
Projected Income Statement - Annual - Protagonist Therapeutics, Inc.
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
141
Date Price Change Volume
06/26/06 $132.04 -2.38% 9,72,945
05/26/05 $135.26 -5.66% 5,84,678
04/26/04 $143.37 +2.23% 7,77,232
03/26/03 $140.24 +0.62% 6,74,722
02/26/02 $139.37 -3.78% 4,86,660
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Protagonist Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
132.04USD
Average target price
178.57USD
Spread / Average Target
+35.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Protagonist Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PTGX Stock